dipyridamole has been researched along with Secondary Hyperparathyroidism in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the value of preoperative dipyridamole thallium-201 scintigraphy for reducing cardiovascular complication in secondary hyperparathyroidism (SHPTH) patients." | 7.88 | Applying preoperative dipyridamole thallium-201 scintigraphy for preventing cardiac mortality and complications for patients with secondary hyperparathyroidism undergoing parathyroidectomy. ( Chi, SY; Chou, FF; Wu, SC; Yin, SM, 2018) |
| "To evaluate the value of preoperative dipyridamole thallium-201 scintigraphy for reducing cardiovascular complication in secondary hyperparathyroidism (SHPTH) patients." | 3.88 | Applying preoperative dipyridamole thallium-201 scintigraphy for preventing cardiac mortality and complications for patients with secondary hyperparathyroidism undergoing parathyroidectomy. ( Chi, SY; Chou, FF; Wu, SC; Yin, SM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, SM | 1 |
| Chou, FF | 1 |
| Wu, SC | 1 |
| Chi, SY | 1 |
| Kaya, B | 1 |
| Altun, E | 1 |
| Paydas, S | 1 |
| Balal, M | 1 |
2 other studies available for dipyridamole and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Applying preoperative dipyridamole thallium-201 scintigraphy for preventing cardiac mortality and complications for patients with secondary hyperparathyroidism undergoing parathyroidectomy.
Topics: Adult; Aged; Coronary Artery Disease; Dipyridamole; Female; Follow-Up Studies; Humans; Hyperparathyr | 2018 |
The efficacy of dipyridamole in the treatment of hypophosphatemia- hypocalcemia for hungry bone syndrome in a hemodialysis patient.
Topics: Adult; Bone Diseases, Metabolic; Dipyridamole; Female; Humans; Hyperparathyroidism, Secondary; Hypoc | 2015 |